Introduction
Portal hypertension is associated with the most severe complications of cirrhosis, including ascites, hepatic encephalopathy, and bleeding from gastro-esophageal varices. Despite the progress achieved over the last decades, the 6-week mortality associated with variceal bleeding is still in the order of 10-20%. Awareness of the difficulty inherent to the evaluation of diagnostic tools and the design and conduct of good clinical trials for the treatment of portal hypertension has led to the organization, since 1986, of a series of consensus meetings. The first one was organized by Andrew Burroughs in Groningen, The Netherlands [1] . After Groningen, other meetings followed, in Baveno in 1990 (Baveno I) [2] and in 1995 (Baveno II) [3, 4] , in Milan in 1992 [5] , in Reston, USA, in 1996 [6] , in Stresa in 2000 (Baveno III) [7, 8] , again in Baveno in 2005 (Baveno IV) [9, 10] , and in Atlanta in 2007 [11] .
The aims of these meetings were to develop definitions of key events in portal hypertension and variceal bleeding, to review the existing evidence on the natural history, the diagnosis and the therapeutic modalities of portal hypertension, and to issue evidence-based recommendations for the conduct of clinical trials and the management of patients. All these meetings were successful and produced consensus statements on some important points, although some issues remained unsettled.
To continue the work of the previous meetings, a Baveno V workshop was held on May 21-22, 2010. The workshop was attended by many of the experts responsible for most of the major achievements of the last years in this field. Many of them had attended the previous meetings as well.
The main fields of discussion of the Baveno V workshop were the same as in Baveno I-IV, i.e. the definitions of key events concerning the bleeding episode and the therapeutic options in patients with portal hypertension. For each of these topics, a series of consensus statements were discussed and agreed upon. As in Baveno IV, whenever applicable, the level of existing evidence was evaluated and the recommendations were ranked according to the Oxford System [12] (i.e.: level of evidence from 1 = highest to 5 = lowest; grade of recommendation from A = strongest, to D = weakest).
The presentations given during the workshop are reported 'in extenso' in the Baveno V proceedings [13] . A summary of the most important conclusions is reported here.
Definition of key events regarding the bleeding episode
Definitions and criteria to evaluate failure to control bleeding and failure to prevent re-bleeding were introduced at Baveno II [3, 4] and reviewed at Baveno III [7, 8] . Since it was found that some of them were rather difficult to apply and did not adequately reflect the situation in clinical practice, new definitions and criteria were proposed at Baveno IV [9, 10] .
The Baveno IV criteria are reported below:
Baveno IV definitions and criteria for failure to control bleeding
(1) The time frame for the acute bleeding episode should be 120 h (5 days). (2) Failure signifies the need to change therapy: one criterion defines failure, whichever occurs first: a. Fresh hematemesis P2 h after the start of a specific drug treatment or therapeutic endoscopy. In the minority of patients who have a naso-gastric tube in place, aspiration of greater than 100 ml of fresh blood represents failure. Baveno IV definitions and criteria for failure of secondary prophylaxis
Failure to prevent re-bleeding is defined as a single episode of clinically significant re-bleeding from portal hypertensive sources. Clinically significant re-bleeding: (a) Hematemesis/melaena. In the minority of patients who have a naso-gastric tube in place, aspiration of greater than 100 ml of fresh blood represents failure, plus (b) Adjusted Blood Requirement Index (ABRI) P0.5 (The threshold of ABRI defining failure requires validation), or (c) Decrease 3 g of Hb if no transfusion is given. After Baveno IV, the diagnostic performance of the Baveno II-III and Baveno IV criteria was evaluated by analysing the population of a study of the use of recombinant factor VII in acute variceal bleeding [14] . The conclusions of the study were as follows: Baveno IV criteria have a rather high accuracy; ABRI in its current definition does not add to the accuracy of the other Baveno IV criteria; the best timing for measurement of hematocrit and the ideal cut off value of ABRI score should be further investigated.
As a consequence, at Baveno V the Baveno IV consensus statements were modified as follows:
Baveno V definitions and criteria for failure to control bleeding -The time frame for the acute bleeding episode should be 120 h (5 days). -Failure is defined as death or need to change therapy defined by one of the following criteria: (2b;B) -Fresh hematemesis or NG aspiration of P100 ml of fresh blood P2 h after the start of a specific drug treatment or therapeutic endoscopy. -Development of hypovolaemic shock. Patients with medium-large varices -Either NSBB or endoscopic band ligation (EBL) is recommended for the prevention of the first variceal bleeding of medium or large varices (1a; A). -The choice of treatment should be based on local resources and expertise, patient preference and characteristics, side effects, and contra-indications (5;D).
-Carvedilol is a promising alternative (1b;A) which needs to be further explored. -Shunt therapy, endoscopic sclerotherapy, and isosorbide mononitrate alone should not be used in the prophylaxis of first variceal bleeding (1a;A). -There is insufficient data to recommend the use of NSBB in combination with Isosorbide-5-Mononitrate (ISMN), spironolactone, or EBL for primary prophylaxis (1b;A).
Patients with gastric varices
-Despite the absence of specific data on prophylactic studies, patients with gastric varices may be treated with NSBB (5;D).
Role of HVPG measurement
-In centers where adequate resources and expertise are available, HVPG measurements should be routinely used for prognostic and therapeutic indications (5;D). -Controlled trials using pharmacological therapy in primary prophylaxis should include HVPG measurements (5;D). -A decrease in HVPG of at least 20% from baseline or to 612 mm Hg after chronic treatment with NSBB is clinically relevant in the setting of primary prophylaxis (1a;A). -Acute HVPG response to intravenous propranolol may be used to identify responders to beta-blockers, specifically a decrease in HVPG of 10% or to 612 mm Hg may be relevant in this setting (1b;A).
Areas requiring further study
-Studies evaluating the use of carvedilol.
-Studies evaluating novel therapeutic options.
Treatment of acute bleeding from varices
Blood volume restitution -The goal of resuscitation is to preserve tissue perfusion. Volume restitution should be initiated to restore and maintain hemodynamic stability. -PRBC transfusion should be done conservatively at a target hemoglobin level between 7 and 8 g/dl., although transfusion policy in individual patients should also consider other factors such as co-morbidities, age, hemodynamic status and ongoing bleeding (1b;A). -Recommendations regarding management of coagulopathy and thrombocytopenia cannot be made on the basis of currently available data (5;D). -PT/INR is not a reliable indicator of the coagulation status in patients with cirrhosis (1b;A).
Antibiotic prophylaxis
-Antibiotic prophylaxis is an integral part of therapy for patients with cirrhosis presenting with upper gastrointestinal bleeding and should be instituted from admission (1a;A). -Oral quinolones are recommended for most patients (1b;A). -Intravenous ceftriaxone should be considered in patients with advanced cirrhosis (1b;A), in hospital settings with high prevalence of quinolone-resistant bacterial infections and in patients on previous quinolone prophylaxis (5;D).
Prevention of hepatic encephalopathy
-Recommendations regarding management and prevention of encephalopathy in patients with cirrhosis and upper GI bleeding cannot be made on the basis of currently available data (5;D).
Assessment of prognosis
-HVPG P20 mm Hg, Child-Pugh class C, and active bleeding at endoscopy are the variables most consistently found to predict 5-day treatment failure (2b;B). -Child-Pugh class C, MELD score P 18, and failure to control bleeding or early re-bleeding are the variables most consistently found to predict 6-week mortality (2b;B).
Timing of endoscopy 
Endoscopic treatment
-Endoscopic therapy is recommended in any patient who presents with documented upper GI bleeding and in whom esophageal varices are the cause of bleeding (1a;A). -Ligation (EVL) is the recommended form of endoscopic therapy for acute esophageal variceal bleeding, although sclerotherapy may be used in the acute setting if ligation is technically difficult (1b;A). -Endoscopic therapy with tissue adhesive (e.g. N-butyl-cyanoacrylate) is recommended for acute bleeding from isolated gastric varices (IGV) (1b;A) and those gastro-esophageal varices type 2 (GOV2) that extend beyond the cardia (5;D). -EVL or tissue adhesive can be used in bleeding from gastroesophageal varices type 1 (GOV1) (5;D).
Early TIPS placement
-An early TIPS within 72 h (ideally 624 h) should be considered in patients at high-risk of treatment failure (e.g. Child-Pugh class C <14 points or Child class B with active bleeding) after initial pharmacological and endoscopic therapy (1b;A).
Use of balloon tamponade
-Balloon tamponade should only be used in massive bleeding as a temporary ''bridge" until definitive treatment can be instituted (for a maximum of 24 h, preferably in an intensive care facility) (5;D).
Use of self-expandable metal stents
-Uncontrolled data suggest that self-expanding covered esophageal metal stents may be an option in refractory Position Paper esophageal variceal bleeding, although further evaluation is needed (4;C).
Management of treatment failures
-Persistent bleeding despite combined pharmacological and endoscopic therapy is best managed by TIPS with PTFE-covered stents (2b;B). -Re-bleeding during the first 5 days may be managed by a second attempt at endoscopic therapy. If re-bleeding is severe, PTFE-covered TIPS is likely the best option (2b;B).
Areas requiring further study -The need for correction of coagulation disorders. Influence of coagulopathy and thrombocytopenia on outcome. -Improve prognostic models: Better stratification of risk to determine timing of the initial endoscopy, duration of drug therapy and type of treatment. 
Patients with cirrhosis
-Combination of beta-blockers and band ligation is the preferred therapy as it results in lower re-bleeding compared to either therapy alone (1a;A). -Hemodynamic response to drug therapy provides information about re-bleeding risk and survival (1a;A). -The addition of ISMN to beta-blockers may improve the efficacy of treatment in hemodynamic non-responders (5;D).
Patients with cirrhosis who are unable or unwilling to be treated with EVL -Beta-blockers with Isosorbide Mononitrate is the preferred option (1a;A).
Patients with cirrhosis who have contra-indications or intolerance to beta-blockers -Band ligation is the preferred treatment (5;D).
Patients who fail endoscopic and pharmacological treatment for the prevention of re-bleeding -Transjugular Intra-hepatic Porto-systemic Shunt (TIPS) with Polytetrafluoroethylene (PTFE)-covered stents is effective and is the preferred option. Surgical shunt in Child-Pugh A and B patients is an alternative if TIPS is unavailable (2b;B).
-Transplantation provides good long-term outcomes in appropriate candidates and should be considered (2b;B). TIPS may be used as a bridge to transplantation (4;C).
Patients who have bled from isolated gastric varices type I (IGV1) or gastro-oesophageal varices type 2 (GOV2)
-N-butyl-cyanoacrylate (1b;A) or TIPS (2b;B) are recommended.
Patients who have bled from gastro-oesophageal varices type 1 with (GOV1) -May be treated with N-butyl-cyanoacrylate, band ligation of oesophageal varices or beta-blockers (2b;B).
Patients who have bled from portal hypertensive gastropathy -Beta-blockers (1b;A) should be used for prevention of recurrent bleeding.
Patients in whom beta-blockers are contraindicated or fail and who cannot be managed by non-shunt therapy -TIPS (4;C) or surgical shunts (4;C) should be considered.
Non-cirrhotic portal hypertension
Similar to Baveno IV, a session in Baveno V was devoted to noncirrhotic portal hypertension, focusing on the Budd-Chiari syndrome and extra-hepatic portal vein obstruction.
Budd-Chiari syndrome [BCS -hepatic venous outflow tract obstruction (HVOTO)]
Definition -Budd-Chiari syndrome can be located from the level of the small hepatic veins to the level of the termination of inferior vena cava into the right atrium. -BCS is a heterogeneous condition with regard to causes and pathogenesis. -BCS is considered secondary when the mechanism for HVOTO is compression/invasion by a benign or malignant tumour, abscess or cyst. -BCS is considered primary otherwise.
Aetiology
-Myeloproliferative diseases should be investigated in all patients with primary BCS, first by testing for V617F JAK2 mutation in peripheral blood. When V617F JAK2 is undetectable, further tests for myeloproliferative diseases should be performed (e.g. molecular testing and bone marrow biopsy) (2b;B). -When liver synthetic function is impaired, low plasma levels of antithrombin, protein C, and protein S should not be considered as specific for an inherited defect unless it is already known in family members. Similarly, anticardiolipin antibodies at low titres and increased serum homocysteine levels may not reflect underlying prothrombotic conditions (3b;B).
Diagnosis
-BCS is diagnosed by the demonstration of an obstruction of the venous lumen, or by the presence of hepatic vein collaterals (4;C).
-Liver biopsy is not necessary to make a diagnosis of BCS when vascular imaging has demonstrated obstruction of the hepatic venous outflow tract (4;C). -Liver biopsy is the only means to make a diagnosis of BCS of the small intra-hepatic veins (4;C). -Hepatic nodules are frequent and most often are benign. HCC may occur and therefore the patient should be referred to centers experienced in managing BCS (5;D). 
Management

Extra-hepatic portal vein obstruction (EHPVO)
Definition -EHPVO is defined by obstruction of the extra-hepatic portal vein with or without involvement of the intra-hepatic portal veins and does not include isolated thrombosis of splenic vein or superior mesenteric vein (SMV). -EHPVO is characterized by features of recent thrombosis or of portal hypertension with portal cavernoma as a sequel of portal vein obstruction. -Presence of cirrhosis and/or malignancy should be stated.
Aetiology
-EHPVO is a heterogeneous entity with regards to causes and pathogenesis.
-EHPVO is frequently associated with one or several risk factors for thrombosis which may be occult at presentation. Common bile duct stricture: Endoscopic stenting; (3b;B) and porto-systemic shunt surgery should be considered, whenever possible, (3b;B). If not relieved by the above, hepatico-jejunostomy may be considered (3b;B).
Chronic EHPVO in children: treatment -Mesenteric-left portal vein bypass (Rex bypass) should be considered in all children with complications of chronic EHPVO, who should be referred to centers with experience in treating this condition (5;D).
Unresolved issues and future studies -Prospective data on the frequency and clinical profile of recent and chronic EHPVO. 
Other issues
In Baveno IV, a session was devoted to predictive models in portal hypertension, during which classification stages of cirrhosis were proposed. Prospective validation of this classification is under way.
Conclusions
The purpose of the consensus definitions about the variceal bleeding episode is to use them in trials and other studies on portal hypertension, as well as in clinical practice. This does not mean that authors cannot use their own definitions, but they are encouraged to use and evaluate in parallel these Baveno V consensus definitions. This should result in some measure of standardisation and increased ease of interpretation among different studies. Equally important, if there are uniformly defined end-points, meta-analyses will be based on more homogeneous studies, which is an essential pre-requisite of this methodology. It is desirable that future studies be reported using these definitions as part of the evaluation. Change or refinement can then take place, as they have at Baveno V with respect to the previous consensus meetings, to ensure that the consensus definitions do have clinical relevance and are easily applied in practice.
Several definitions agreed upon in the previous Baveno workshops were taken for granted and not discussed in Baveno V. Interested readers can refer to the Baveno I-IV reports [2] [3] [4] [7] [8] [9] [10] .
The suggestions about the topics of future studies reflect the opinions of the experts about the areas where new information is most needed.
As long as new diagnostic tools and new treatments appear, they will have to be assessed in comparison with present-day standards.
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